- Vivos Therapeutics filed a Form 12b-25 to delay its Form 10-K for fiscal year ended Dec. 31, 2025.
- Filing cited added time needed to complete year-end financial statements tied to 2025 acquisition of Sleep Center of Nevada.
- Report is expected within 15 days of original due date under SEC late-filing extension.
- Preliminary view points to revenue up more than 15% year over year.
- Sales, general and administrative expenses are expected to rise about 50%, with net loss projected to widen.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-014114), on March 31, 2026, and is solely responsible for the information contained therein.
Comments